Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 20/20 | 1.00 |
| ▸ | ICAM1 | P05362 | 20/20 | 1.00 |
| ▸ | ITGAL | P20701 | 20/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16307478 | 1.00 | ITGB2 (1.00) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL10129607 | 0.93 | ITGB2 (0.90) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL19158058 | 0.92 | ITGB2 (0.86) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL10168219 | 0.91 | ITGB2 (0.83) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL13185744 | 0.90 | ITGB2 (0.82) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL13167912 | 0.90 | ITGB2 (0.82) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL13813604 | 0.90 | ITGB2 (0.87) | ITGB2ICAM1ITGAL | |
| SCHEMBL4755821 | 0.90 | ITGB2 (0.81) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL10129644 | 0.89 | ITGB2 (1.00) | ITGB2ICAM1ITGAL | |
| SCHEMBL13658130 | 0.89 | ITGB2 (0.80) | ITGB2ICAM1ITGAL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-09-14 | — | — | US | disclosed |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-09-14 | — | — | US | disclosed |
| US-20230233551-A1 | COMPOSITIONS AND METHODS FOR TREATMENT | CITIBANK, N.A., AS NOTES COLLATERAL AGENT | 2023-07-27 | — | — | US | disclosed |
| US-20230233551-A1 | COMPOSITIONS AND METHODS FOR TREATMENT | CITIBANK, N.A., AS NOTES COLLATERAL AGENT | 2023-07-27 | — | — | US | disclosed |
| US-20230050819-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-02-16 | — | — | US | disclosed |
| US-20210338839-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC RETINOPATHY | NOVARTIS AG (CH) | 2021-11-04 | — | — | US | disclosed |
| US-20210283265-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-09-16 | — | — | US | disclosed |
| US-20210284629-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-09-16 | — | — | US | disclosed |
| US-20210238226-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-08-05 | — | — | US | disclosed |
| US-20210228723-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-07-29 | — | — | US | disclosed |
| US-20100093693-A1 | MODULATORS OF CELLULAR ADHESION | BAUSCH + LOMB IRELAND LIMITED (IE) | 2010-04-15 | — | — | US | disclosed |
| US-20100093693-A1 | MODULATORS OF CELLULAR ADHESION | BAUSCH + LOMB IRELAND LIMITED (IE) | 2010-04-15 | — | — | US | disclosed |
| US-20090155176-A1 | Compositions and methods for treatment of diabetic retinopathy | SARCODE CORPORATION (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090155176-A1 | Compositions and methods for treatment of diabetic retinopathy | SARCODE CORPORATION (US) | 2009-06-18 | — | — | US | disclosed |
| US-20080182839-A1 | MODULATORS OF CELLULAR ADHESION | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-07-31 | — | — | US | disclosed |
| US-20080182839-A1 | MODULATORS OF CELLULAR ADHESION | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-07-31 | — | — | US | disclosed |
| US-20080176896-A1 | Modulators of cellular adhesion | BAUSCH + LOMB IRELAND LIMITED (IE) | 2008-07-24 | — | — | US | disclosed |
| US-20080176896-A1 | Modulators of cellular adhesion | BAUSCH + LOMB IRELAND LIMITED (IE) | 2008-07-24 | — | — | US | disclosed |
| US-7314938-B2 | Immune and/or inflammatory disorders; autoimmune disorders; disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1); antagonize CD11/CD18 receptors associated with leukocytes. | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-01-01 | — | — | US | disclosed |
| US-7314938-B2 | Immune and/or inflammatory disorders; autoimmune disorders; disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1); antagonize CD11/CD18 receptors associated with leukocytes. | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176896-A1 | Modulators of cellular adhesion | ITGB1, VCAM1, ITGB8 | ITGB2 8/4885ICAM1 5/4885ITGAL 11/4885 |
| US-20210238226-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ATXN2L, ATXN2, ATXN10 | ITGB2 2851/4885ICAM1 4240/4885ITGAL 4225/4885 |
| US-20090155176-A1 | Compositions and methods for treatment of diabetic retinopathy | VCAM1, ITGB1, ICAM1 | ITGB2 11/4885ICAM1 3/4885ITGAL 5/4885 |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, CBL, UBQLN2 | ITGB2 4803/4885ICAM1 4630/4885ITGAL 4834/4885 |
| US-20210283265-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, CBL, UBQLN2 | ITGB2 4803/4885ICAM1 4630/4885ITGAL 4834/4885 |
| US-20100093693-A1 | MODULATORS OF CELLULAR ADHESION | ITGB1, VCAM1, ITGB8 | ITGB2 8/4885ICAM1 5/4885ITGAL 11/4885 |
| US-20230050819-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | CYFIP2, TPX2, ATXN2 | ITGB2 4235/4885ICAM1 4547/4885ITGAL 4839/4885 |
| US-20230233551-A1 | COMPOSITIONS AND METHODS FOR TREATMENT | ICAM1, VCAM1, ITGAL | ITGB2 8/4885ICAM1 1/4885ITGAL 3/4885 |
| US-20210338839-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC RETINOPATHY | VCAM1, ITGB1, ICAM1 | ITGB2 11/4885ICAM1 3/4885ITGAL 5/4885 |
| US-20210228723-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ZFX, F13B, GRN | ITGB2 2628/4885ICAM1 4275/4885ITGAL 3924/4885 |
| US-20080182839-A1 | MODULATORS OF CELLULAR ADHESION | ITGB1, VCAM1, ITGB8 | ITGB2 8/4885ICAM1 5/4885ITGAL 11/4885 |
| US-20210284629-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, UBQLN2, UBTF | ITGB2 4670/4885ICAM1 4564/4885ITGAL 4765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.